Digestive Tract Ulcer Affecting Patents (Class 514/13.2)
  • Patent number: 10039811
    Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 7, 2018
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 9816997
    Abstract: The present invention is related to the anti-SOX10 antibodies, kits, cocktails, and use of anti-SOX10 antibodies for detection of cancer.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 14, 2017
    Assignee: Biocare Medical, LLC
    Inventors: David Tacha, Weimin Qi
  • Patent number: 9347037
    Abstract: A novel method for building complex three-dimensional scaffolds for biomimetic applications such as in vitro organ growth, using a gelatin/sugar/water gel, ultraviolet radiation, and heat or enzyme is described. The method produces gelatin-sugar hydrogels demonstrating greater thermal stability, mechanical strength, and resistance to enzymatic degradation. The invention also provides a means to assemble the gelatin sugar hydrogel films into complex three-dimensional structures (scaffolds). To account for the native biochemical factors present in natural scaffolds, methods of conjugating such factors to the gelatin-sugar hydrogel are described. These scaffolds can then be applied for tissue culturing and organ growth. The present invention also describes a system and apparatus for constructing these complex three-dimensional scaffolds by taking advantage of the physical and chemical properties of the gelatin-sugar hydrogel.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: May 24, 2016
    Inventors: Evan Masataka Masutani, Brandon Aran Yoza, Travis Tadashi Tanaka, Christopher Randall Russ, Andrew Kevin Donald Ellison, Dominic Seth Reiss
  • Publication number: 20150148290
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Application
    Filed: October 31, 2014
    Publication date: May 28, 2015
    Inventors: Eric Marsault, Carl St-Louis
  • Publication number: 20150119328
    Abstract: Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.
    Type: Application
    Filed: January 5, 2015
    Publication date: April 30, 2015
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian Cali
  • Publication number: 20150104485
    Abstract: Compounds of general formula (I): Ri—Wn—Xm-AAi-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, pigmentation disorders and angiogenic skin disorders, and in processes of treatment and/or care of the skin and/or mucous membranes.
    Type: Application
    Filed: April 16, 2013
    Publication date: April 16, 2015
    Applicant: LUBRIZOL ADVANCED MATERIALS, INC.
    Inventors: Jose Maria Garcia Anton, Antonio Vicente Ferrer Montiel, Cristina Carreño Serraïma, Raquel Delgado González, Juan Cebrián Puche
  • Publication number: 20150099693
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 9, 2015
    Applicants: KAEL-GEMVAX CO., LTD., GEMVAX-AS
    Inventors: Sang Jae Kim, Kyun Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20150099692
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 9, 2015
    Applicants: KAEL-GEMBAX CO., LTD., GEMVAX AS
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20150094265
    Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: December 1, 2014
    Publication date: April 2, 2015
    Inventors: ANGELIKA FRETZEN, HONG ZHAO, MARCO KESSLER
  • Publication number: 20150094266
    Abstract: Compositions include synergistic combinations of xyloglucans and vegetable or animal proteins that are useful in the treatment of intestinal disorders or of disorders originating from the intestinal system and transferred to other systems, such as the genitourinary system. The compositions include xyloglucans or an extract containing xyloglucans, and one or more animal or vegetable proteins. Methods for the treatment or prevention of intestinal disorders are provided, including prevention of diarrhoea.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 2, 2015
    Applicant: Novintethical Pharma, SA
    Inventors: Marco Di Fulvio, Miguel Angel Alonso, Michele Giuseppe Di Schiena
  • Patent number: 8993522
    Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: March 31, 2015
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Sadasivan Vidyasagar, Paul Okunieff, Lurong Zhang
  • Patent number: 8957032
    Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: February 17, 2015
    Assignee: Alba Therapeutics Corporation
    Inventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
  • Publication number: 20150037350
    Abstract: The invention provides means for treating Th1- and Th2-mediated diseases, such as asthma, allergic dermatitis and Th2-driven cancer. The invention extends to pharmaceutical compositions for use in treating such conditions, and to methods of treatment. The invention also extends to adjuvants and vaccines per se, and to their use in enhancing the immunomodulatory activity of immunogens.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 5, 2015
    Applicant: UCL BUSINESS PLC
    Inventors: Anna L. Furmanski, Jose Ignacio Saldana, Tessa Crompton
  • Patent number: 8946158
    Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 3, 2015
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel Zimmer
  • Patent number: 8933030
    Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: January 13, 2015
    Assignee: Ironwwod Pharmaceuticals, Inc.
    Inventors: Angelika Fretzen, Hong Zhao, Marco Kessler
  • Patent number: 8916517
    Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: December 23, 2014
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: David H. Coy, Jerome L. Maderdrut, Min Li
  • Patent number: 8901075
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: December 2, 2014
    Assignee: Synergy Pharmaceuticals, Inc.
    Inventors: Kunwar Shailubhai, Gary S. Jacob
  • Publication number: 20140336106
    Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 13, 2014
    Applicant: Onyx Therapeutics, Inc.
    Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
  • Publication number: 20140336119
    Abstract: The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(Xa)P3(Xb)P5(Xc)P6(Xd)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 13, 2014
    Applicant: INSTITUT PASTEUR
    Inventors: Benoit Marteyn, Yves-Marie Coic, Francoise Baleux, Philippe Sansonetti
  • Publication number: 20140329738
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Application
    Filed: March 28, 2014
    Publication date: November 6, 2014
    Inventors: Kunwar Shailubhai, Gary S. Jacob
  • Publication number: 20140329753
    Abstract: This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity.
    Type: Application
    Filed: May 2, 2013
    Publication date: November 6, 2014
    Inventor: JESSE MICHAEL JAYNES
  • Publication number: 20140322302
    Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.
    Type: Application
    Filed: May 11, 2014
    Publication date: October 30, 2014
    Applicant: COMBIMAB, INC
    Inventors: Henry Wolfe, Reinhard Ebner
  • Publication number: 20140294901
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 2, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • Publication number: 20140287001
    Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Inventor: Kunwar Shailubhai
  • Publication number: 20140255374
    Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.
    Type: Application
    Filed: November 6, 2013
    Publication date: September 11, 2014
    Applicant: CERULEAN PHARMA INC.
    Inventor: Scott Eliasof
  • Publication number: 20140256634
    Abstract: Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 11, 2014
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian Cali
  • Publication number: 20140248348
    Abstract: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.
    Type: Application
    Filed: January 19, 2012
    Publication date: September 4, 2014
    Applicants: SUZHOU SCISCAPE BIOMEDICINE SCIENCE & TECHNOLOGY CO. LTD., PEOPLE'S LIBERATION ARMY OF CHINA
    Inventors: Chenggang Zhang, Junhuai Li, Yang Xu, Yonghong Wu, Weiguang Li, Yanchun Zhang, Yan Gao, Zhihui Li
  • Patent number: 8796203
    Abstract: The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: August 5, 2014
    Assignee: Alba Therapeutics Corporation
    Inventors: Blake Paterson, Amir Tamiz, Niranjan Pandey
  • Publication number: 20140206598
    Abstract: The invention provides a L19 source as a medicament, preferably for preventing or treating an inflammatory disorder in an individual.
    Type: Application
    Filed: May 8, 2012
    Publication date: July 24, 2014
    Applicant: LABORATORIOS LETI, S.L.
    Inventors: Carlos Alonso Bedate, Manuel Soto Alvarez, Laura Ramirez Garcia, Jeronimo Carnés - Sánchez, Marta Román Escutia
  • Publication number: 20140193465
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: October 10, 2013
    Publication date: July 10, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • Publication number: 20140187470
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer), a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder) by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.
    Type: Application
    Filed: January 2, 2014
    Publication date: July 3, 2014
    Inventors: Gary S. Jacob, Kunwar Shailubhai
  • Publication number: 20140187474
    Abstract: A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.
    Type: Application
    Filed: March 6, 2014
    Publication date: July 3, 2014
    Inventor: Justin L. Sonnenburg
  • Publication number: 20140179607
    Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.
    Type: Application
    Filed: November 9, 2010
    Publication date: June 26, 2014
    Applicant: IRONWOOD PHARMACEUTICALS, INC
    Inventors: Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel P. Zimmer
  • Patent number: 8728475
    Abstract: Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-? are disclosed, as are other methods.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: May 20, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Timothy Zheng
  • Patent number: 8716224
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: May 6, 2014
    Assignee: Synergy Pharmaceuticals Inc.
    Inventors: Kunwar Shailubhai, Gary S. Jacob
  • Publication number: 20140088015
    Abstract: The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGF like domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 27, 2014
    Inventors: Samuel B. Ho, Laurie L. Shekels
  • Publication number: 20140073571
    Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: February 17, 2011
    Publication date: March 13, 2014
    Inventors: Angelika Fretzen, Hong Zhao, Marco Kessler
  • Publication number: 20140045756
    Abstract: The present disclosure relates to methods and compositions for modulating TNF and TNFR signaling. In particular, the disclosure describes methods and compositions for inhibiting TNF? signaling, such as in the prevention or treatment of TNF?-related diseases.
    Type: Application
    Filed: March 9, 2012
    Publication date: February 13, 2014
    Applicant: New York University
    Inventor: Chuan-Ju Liu
  • Publication number: 20140037634
    Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g.
    Type: Application
    Filed: May 24, 2013
    Publication date: February 6, 2014
    Inventors: Randolph J. Noelle, Li Wang
  • Publication number: 20140030251
    Abstract: Compositions and methods for preventing or ameliorating tissue damage caused by an inflammatory disorder or pathogenic infections are described. In one aspect, a method for preventing or ameliorating tissue damage caused by an inflammatory disorder or pathogenic infection comprises administering to a subject a therapeutically effective amount of a neuregulin. In another aspect, the composition comprises one or more active agents that: (a) increase expression or activity of a neuregulin; (b) inhibit the expression or activity of CXCL10, STAT3 or HEME; or (c) both (a) and (b).
    Type: Application
    Filed: July 24, 2012
    Publication date: January 30, 2014
    Applicant: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Byron D. Ford, Jonathan Stiles, Gregory Ford
  • Publication number: 20140024593
    Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 23, 2014
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventor: Ironwood Pharmaceuticals, Inc.
  • Publication number: 20140018286
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 16, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
  • Publication number: 20140011732
    Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B—C—, or A-B—C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 9, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Soeren Oestergaard, Steffen Reedtz-Runge, Henning Thoegersen
  • Patent number: 8603489
    Abstract: The invention refers to compositions that comprise the protein preparation, obtained from the latex of Hevea brasiliensis, in a low concentration. Additionally, the invention refers to the use of the protein preparation or the composition described herein, for the preparation of a medicine to treat chronic inflammatory diseases, and to the method of treating same that uses the aforementioned composition or the protein preparation.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: December 10, 2013
    Assignee: Pele Nova Biotecnologia S.A.
    Inventor: Fatima Mrue
  • Patent number: 8603978
    Abstract: The present invention provides a method of treating or preventing inflammation in a subject comprising administering to the subject an effective amount of a muramyl dipeptide (MDP).
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: December 10, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Humand Services
    Inventors: Warren Strober, Ivan Fuss, Atsushi Kitani, Peter Mannon, Tomohiro Watanabe
  • Patent number: 8592378
    Abstract: The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a culture broth, a pharmaceutical composition containing the compound, and uses of the compound.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: November 26, 2013
    Assignee: Telsar Pharma Inc.
    Inventors: Takanao Otsuka, Hirotsugu Ueda, Keiko Fujie, Hideyuki Muramatsu, Michizane Hashimoto, Shigehiro Takase
  • Patent number: 8586537
    Abstract: A method for treating recurrent minor aphthous ulcers is provided in which a sufferer is treated with a combination therapy of Vitamin B6 and B12 compounds. The treatment is done orally and the treatment minimizes the duration and pain of the sore, as well as increasing the period of time between recurrences.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: November 19, 2013
    Inventor: Rick Tope
  • Publication number: 20130296224
    Abstract: The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators. Exemplary modulators include inhibitors of PKC-alpha, PKC-epsilon and PKC-eta, as well as activators of PKC-delta.
    Type: Application
    Filed: January 23, 2013
    Publication date: November 7, 2013
    Inventors: Liora BRAIMAN-WIKSMAN, Tamar TENNENBAUM, Yuval SAGIV, Marina GARTSBEIN, Ephraim BRENER, Moshe BEN-HAMO, Liat HAMMER
  • Publication number: 20130244927
    Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.
    Type: Application
    Filed: February 15, 2012
    Publication date: September 19, 2013
    Inventors: Preeti Lal, Y. Tom Tang, Gina A. Gorgone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice Au-Young, Henry Yue, Chandra Patterson, Roopa Reddy, Jennifer L. Hillman, Olga Bandman
  • Publication number: 20130236509
    Abstract: The invention relates to a biodegradable microparticle having a diameter between 0.2 and 3.5 micrometer and comprising a pharmaceutically effective amount of at least one small heat-shock protein that induces IL-10 production in macrophages, said small heat-shock protein comprising an amino acid sequence identity of at least 50% to any of the sequences listed as SEQ ID NOs: 1 and 12-26.
    Type: Application
    Filed: July 14, 2011
    Publication date: September 12, 2013
    Applicant: DELTA CRYSTALLON B.V.
    Inventor: Johannes Maria Van Noort